eRx Script Exchange Pty Ltd (eRx) seeks authorisation to continue to operate its Prescription Exchange System interoperably with IP MDS Pty Ltd's (formerly MediSecure) Prescription Exchange System and vice versa. Specifically, authorisation is sought for the parties to share equally in the fee which is charged to a pharmacy user and the Australian Government by the Prescription Exchange System to which a pharmacy is connected in respect of each prescription that has originated on the Prescription Exchange System of the other party (as outlined in Clause 14 of the Commercial Interchange Agreement).
On 7 June 2017 the ACCC granted interim authorisation to the revenue sharing arrangement. Interim authorisation commenced immediately and remains in place unless it is revoked or the date the ACCC's final determination comes into effect.
On 31 August 2017 the ACCC issued a draft determination proposing to grant authorisation to eRx to continue to give effect to the revenue sharing arrangement until 30 June 2020.
The ACCC will now consider submissions in response to the draft determination before issuing a final decision.
Further information about the draft determination and how to make a submission is available from the Decisions and Correspondence links below.